Thursday, February 20, 2014

Available Now! The RNAi Therapeutics Investment Guide for 2014

Starting today, the 2014 sequel to the inaugural RNAi Therapeutics Investment Guide published in 2013 is available. 

Who should read the Guide?

The Guide should be particularly useful for pharmaceutical business development people and executives as well as investors in the public stock markets (esp. biotech) in order to gain a broader understanding of the technical, regulatory, and economic context of RNAi Therapeutics drug development.  Investment opportunities and related risks will become apparent.

Specifically, the Guide

a)      Recaps the most important technical, clinical, capital markets, and business development events related to RNAi Therapeutics in 2013 leading up to a snapshot of the current industry status.  This includes putting these topics in the context of broader economic and regulatory trends as well as the field of Oligonucleotide/RNA Therapeutics;

b)      Provides an outlook on 2014, particularly a discussion of important RNAi Therapeutics product candidates and upcoming clinical read-outs in 2014.  In addition, it will give a sense of how the year may play out in the capital markets (business development and stock markets) in more general terms;

c)      Discusses strategies and valuations of key RNAi Therapeutics players, including Alnylam, Arrowhead Research, Benitec, Dicerna, Marina Biotech, RXi Pharmaceuticals, and Tekmira.  

~30 pages (as pdf email attachment)


Drug development companies up to 10 employees: 500 Euros/650 US dollars
Drug development companies over 10 employees: 1000 Euros/1300 US dollars
Other companies (e.g. financial institutions and investment funds): 800 Euros/1100 US dollars
University libraries: 95 Euros/130 dollars
Individuals (private use only): 140 Euros/ 195 US dollars

Prices exclude 19% VAT for German customers (corporate and non-corporate) and non-corporate customers in the European Union.

Payments either by check, bank transfer or paypal.

When ordering, the following information is required:

Full name and address
Use (corporate, individual etc)
Billing name and address if different

Order by contacting me at
My first name: dirk; my last name: haussecker


Anonymous said...

Dirk, if I were to order a copy would I get to read about endosomal escape hatch technology? And who it is that is blazing a trail in this area?

Dirk Haussecker said...

I'm afraid not really.

Anonymous said...

Dirk, you should help Marina Biotech discover a polymer delivery system so they could be the one stop shop for oligo therapeutics!

Anonymous said...

It is time for a new poll for 2014...

Dirk Haussecker said...

Well, the answer would be already known for that...Sanofi/Genzyme.

Anonymous said...

I hope this one is on your list.

BLT's ddRNAi coming in to play yet again.

Gene therapy biopharma uniQure sets terms for $64 million IPO


uniQure, which develops gene therapies for the treatment of orphan diseases, announced terms for its IPO on Friday. The Amsterdam, Netherlands-based company plans to raise $64 million by offering 4.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, uniQure would command a market value of $235 million.

uniQure, which was founded in 1998 and booked $3 million in license and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. uniQure initially filed confidentially on November 8, 2013. Jefferies, Leerink Partners and Piper Jaffray are the joint bookrunners on the deal

CPNS 2014 said...

Thanks for the Guide

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.